NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,016,500.00
Award Year:
2005
Program:
SBIR
Phase:
Phase II
Contract:
2R44AR049621-02
Agency Tracking Number:
AR049621
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Molecular Design International, Inc.
Molecular Design International, 2701 Union Ave Ext, Ste 405, Memphis, TN, 38112
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
WILLIAM PURCELL
(901) 454-0797
purcell@moleculardesign.com
Business Contact:
WILLIAM PURCELL
(901) 454-0797
PURCELL@MOLECULARDESIGN.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried out prior to Phase I and during the Phase I portion of this project have demonstrated that a synthetic retinoid (identified as MDI-301) is as effective as all-trans retinoic acid (RA) in stimulating collagen repair in the dermis of mice (topically treated) and human skin (in organ culture) but, unlike RA, is non-irritating. We expect, therefore, that MDI-301 will ultimately provide a non-irritating alternative to RA for topical use in the prevention and treatment of aged/photoaged skin. In this Phase II application, we have identified a number of critical issues that need to be addressed as part of the development process of MDI-301. The three specific aims of this Phase II application identify the issues and our approach for addressing each of them. In Specific Aim I we will compare MDI-301 and RA for ability to stimulate extracellular matrix production and inhibit extracellular matrix degradation in human skin transplanted to severe-combined immunodeficient (scid) mice. As part of these studies, we will determine if treatment results in a histologically-evident improvement in the structure of the transplanted skin and determine if function (i.e., wound-healing capacity) is concomitantly improved in the treated skin. In Specific Aim II, MDI-301 and RA will be compared for their ability to modulate events in human skin that contribute to irritation. The information from theses studies will be used to help understand, at the cellular and molecular levels, why MDI-301 is non-irritating under conditions in which RA is irritating. Finally, in Specific Aim III, we will begin the safety evaluation of MDI-301 necessary to file an Investigational New Drug (IND) application with the FDA. The major goal of the Phase II effort is to develop MDI-301 to the point where we can attract a drug-development partner having the resources to obtain regulatory approvals (IND, clinical trials, NDA) and to market the drug effectively.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government